Sufentanil NanoTab PCA System: Phase III started

AcelRx began an open-label, U.S. Phase III trial to compare 15 mg sublingual NanoTabs given every 20 minutes via Sufentanil NanoTab PCA System for 48-72 hours vs. patient-controlled analgesia (PCA) wi...